Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms

Schizophrenia Clinical Trial

— tbTMS_SCH21  

Official title:

Theta-burst rTMS in Schizophrenia to Ameliorate Negative and Cognitive Symptoms: a Double-blind, Randomized Clinical Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT05100888
• Other study ID #: TB-rTMS_SCH2021
• Status: Enrolling by invitation
• Phase: N/A
• Start date: July 11, 2022
• Est. completion date: December 1, 2025

Study information

• Verified date: March 2023
• Source: Semmelweis University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The major target of the study is to confirm the safety and efficacy of our augmented protocol of theta-burst TMS in schizophrenia. Our aim is to confirm the beneficial effects of rTMS treatment on multiple aspects of the disorder such as (1) clinical aspect in terms of PANSS, (2) cognitive aspect such as emotion recognition (ER) and working memory (WM) / distractor filtering (DF) performance, and (3) neurobiology in terms of electrophysiology correlates of ER, WM and DF such as event related theta synchronization, resting state theta power, and network connectivity. Response prediction to (theta-burst) TB-rTMS will be the exploratory part of the study.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 90
• Est. completion date: December 1, 2025
• Est. primary completion date: October 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. diagnosis of schizophrenia or schizoaffective disorder;

2. clinically stabilized on antipsychotic: a stable dose of antipsychotic medication for >4 weeks;

3. age 18-55 years, and

4. presence of negative symptoms (based on PANSS): a negative subscore =16 points and [one of items N1-N7 scoring =4 or two items N1-N7 scoring =3]

Exclusion Criteria:

1. any significant neurological illness;

2. mental retardation

3. history of head injury with loss of consciousness for more than 1 hour

4. history of epileptic seizures or epileptic activity on the baseline EEG (evaluated by an expert in clinical EEG and epilepsy),

5. alcohol or drug abuse within the past 3 months, and

6. depressive episode or antidepressant treatment in the past 4 weeks.

7. Severe positive symptoms inferfere with cognitive tests

8. ECT in the medical history

9. Implanted pacemaker, implanted drug pump, cochlear implant, implanted defibrillator, implanted neurostimulator or any other TMS incompatible implanted metal device

10. Skin surface is severly injured in the stimulated region of the skull

11. Sclerosis multiplex

12. Pregnancy

13. Severe sleep deprivation

14. Severe heart failure

15. Increased intracranial pressure

16. Untreated migrain

Related Conditions & MeSH terms

• Neurobehavioral Manifestations
• Schizophrenia

Intervention

Device:
• repetitive Transcranial Magnetic Stimulation (rTMS)
Theta-burst stimulation

Locations

Country	Name	City	State
Hungary	Department of Psychiatry and Psychotherapy	Budapest

Sponsors (1)

Lead Sponsor	Collaborator
Semmelweis University

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Positive and Negative Syndrome Scale, Negative subscore	The Positive and Negative Syndrome Scale (PANSS) is a medical scale used for measuring symptom severity of patients with schizophrenia. It is the gold standard in the treatment monitoring of schizophrenia.The scale has three subscales : positive, negatve and general symptom score. We use the negative subscore as primary outcome. Its minimum and maximum scores are 7 and 49 respectively. Higher values indicate worse outcome.	4 weeks
Secondary	Cognitive functioning/Short-Term Memory - The Digit Span Forward and Backward tests	They will be used to assess working memory. Digits Recalled is the primary outcome measure ranging between 2 and 10. Lower values indicate worse outcome.	4 weeks
Secondary	Cognitive functioning/Executive functioning - Wisconsin Card Sorting test	The test will be used to measure cognitive flexibility/Executive functioning. Number of persevarative errors is the major outcome variable of the test, its minimum is 0, while it has no theroretical maximum value. Higher values indicate worse outcome. Punishment sensitivity (P) from the reinforcement learning model of WCST will also be used as outcome variable. Its minimum value is 0 and it has no theoretical maximum value. Lower values indicate worse outcome.	4 weeks
Secondary	Social cognition 1 - The Baron-Cohen 'Reading the Mind in the Eyes Test '	The total score is the primary outcome, which ranges between 0 and 37 points. Lower values indicate worse outcome.	4 weeks
Secondary	Social cognition 2 - The 'Faux Pas' test.	Measures Theory of Mind (ToM), and the primary outcome measure is the total score, which ranges between 0 and 1. Lower values indicate worse outcome.	4 weeks
Secondary	Facial Emotion Recogniton - Karolinska Directed Emotional Face set	Facial expression recognition task. Subject have to identify emotional expressions from photographs of 8 male and 8 female subjects. The pictures are chosen from Karolinska Directed Emotional Face set. There are 3 photographs from each faces (happy, neutral, and sad). Hit rate is the primary outcome measure, which ranges from 0% to 100%, and lower values indicate worse outcome.	4 weeks
Secondary	Safety in terms of adverse events	Safety in terms of the number of serious adverse events (SAE).; A Serious Adverse Event is any untoward medical occurrence that: Results in death; Is life-threatening or; Requires in-patient confinement or prolongation of existing confinement or; Results in persistent or significant disability/incapacity or; Is a congenital anomaly/birth defect.	4 weeks